

6th isirv-AVG Conference
Advances in Respiratory Virus Therapeutics

Tuesday 13th - Thursday 15th November 2018
Hilton Washington DC/ Rockville Hotel, Washington DC, USA

Preliminary Programme

Tuesday 13 November	
08:30-08:45	Welcome & Opening
08:45-09:30	Session 1: Keynote Lecture: BARDA Perspectives on Advancing Respiratory Virus Therapeutics <i>Rick Bright, BARDA, Washington, D.C., USA</i>
09:30-11:00	Session 2 : Symposium - Preclinical Topics Eritoran, a TLR 4 Antagonist <i>Stefanie Vogel, University of Maryland, Baltimore, MD, USA</i> Repurposing of drugs as novel influenza (and other respiratory viruses) inhibitors from clinical gene expression infection signatures <i>Andres Pizzorno, Centre International de Recherche en Infectiologie (CIRI-Team VirPath) & Signia Therapeutics, Lyon, France</i> Repurposing Host Targets for Influenza Therapy <i>Kevin Harrod, University of Alabama, Birmingham, AL, USA</i> HA Minibinders Proof-of-Concept in Mice and Ferrets <i>Deborah Fuller, University of Washington, Seattle, WA, USA</i>
11:00-11:30	Coffee Break
11:30-13:00	Session 3: Oral Abstract Session 1- Preclinical Papers
13:00-14:00	Sponsored Lunchtime Seminar - TBC
14:00-15:00	Session 4: Symposium- Clinical Trial Design Issues Clinical Pharmacology Considerations for Influenza and RSV Trials <i>Su-Young Choi, FDA, Silver Spring , MD, USA</i> Considerations of use of PROs in SARI and Hospitalized Influenza Studies <i>Michelle Campbell, FDA, Silver Spring , MD, USA</i>
15:00-15:30	Coffee Break
15:30-17:00	Session 5: Oral Abstracts Session 2- Preclinical and Phase 1 Clinical Papers
17:00-18:00	Welcome Buffet Reception

Wednesday 14 November	
08:30-10:35	<p>Session 6: Symposium - Updates on Clinical Trials</p> <p>Evaluation of Anti-HA Stem Monoclonal Antibody FluA in Two Phase 2 Influenza Studies <i>Melicent Peck, Genentech, South San Francisco, California, USA</i></p> <p>Baloxavir Marboxil, a Cap-Dependent Endonuclease Inhibitor - Development Updates <i>Takeki Uehara, Shionogi & Co., Ltd, Osaka, Japan</i></p> <p>RSV Antiviral Treatment for HCT patients: Results from Recent Phase 2 Studies for Presatovir <i>Michael Boeckh, University of Washington, Seattle, WA, USA</i></p> <p>Overview of RSV and Influenza Programmes <i>James Witek, Janssen Research and Development, Titusville, New Jersey, USA</i></p> <p>Randomized Phase 2 Study Evaluating Nitazoxanide Versus Placebo in Hospitalized Subjects with Severe Acute Respiratory Illness <i>John Beigel, NIAID, Bethesda, MD, USA</i></p>
10:35-11:00	Coffee Break
11:00-13:00	<p>Session 7: Symposium- Clinical Trial and Regulatory Issues</p> <p>FDA Considerations for Influenza Drug Development</p> <ul style="list-style-type: none"> ○ Trial Designs for Serious Influenza ○ Therapeutic Combinations (Antivirals, Adjunctive Therapies) ○ Pediatric Considerations <p><i>Wendy Carter, FDA, Silver Spring, MD, USA</i></p> <p>Statistical Considerations/Endpoints <i>LaRee Tracy, FDA, Silver Spring, MD, USA</i></p> <p>EMA Perspective <i>Radu Botgros, EMA, London, UK</i></p> <p>Investigator Perspective (Influenza) <i>Michael Ison, Northwestern University, Chicago, Illinois, USA</i></p> <p>Discussion on RSV - FDA Guidance for Industry and Trial Designs/Endpoint <i>Prabha Viswanathan, FDA, Silver Spring, MD, USA</i></p> <p>Investigator Perspective (RSV) <i>John DeVincenzo, University of Tennessee, Memphis, Tennessee, USA</i></p>
13:00-14:00	<p>Lunchtime Seminar</p> <p>Clinical Management of MERS – Meet-the-Professor <i>Yaseen Arabi, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia</i></p>
14:00-15:00	<p>Session 8: Roundtable Discussion- Clinical Trial and Regulatory Issues <i>Academic, Regulatory and Industry representatives</i></p>
15:00-15:30	Coffee Break

15:30-17:00	Session 9: Oral Abstract Session 3- Clinical Papers (Including Disease Pathogenesis, Biomarkers, Diagnostics)
17:00-18:00	Poster Session
Thursday 15 November	
08:30-10:00	Session 10: Oral Abstract Session 4- Clinical Trial Papers
10:00-10:30	Coffee Break
10:30-12:30	<p>Session 11: Hot Topics and Late-Breakers</p> <p>Antiviral Resistance Monitoring Strategies <i>Aeron Hurt, WHO Collaborating Centre, Melbourne, Australia</i></p> <p>Antiviral Design Against Emerging and Pre-Epidemic Coronaviruses <i>Ralph Baric, University of North Carolina, Chapel Hill, NC, USA</i></p> <p>Adjunctive Therapies <i>Nelson Lee, University of Alberta, Edmonton, Canada</i></p>
12:30-13:00	Summary and Close of Conference
	Lunch and Depart